An aHUS patient in Ontario recently received temporary funding for Soliris through the province’s Compassionate Review Policy.
The Compassionate Review Policy allows for aHUS patients (through their physicians) to request publicly funded access to the medication.
However, the circumstances under which such a request for Soliris may be granted by the Executive Officer (EO) of the Ontario Public Drug Programs are very specific:
- You must have been urgently hospitalized due to an immediate life-, limb-, or organ- threatening complication related to aHUS
- If granted, the funding approval will be limited to a maximum of 6 months and will begin once you are discharged from the hospital (on an out-patient basis)
- Further extension of funding will only be considered upon demonstration of clinical improvement with Soliris
- Further coverage may not be approved once the EO makes a final decision on funding Soliris
A copy of the Compassionate Review Policy can be found at: http://www.health.gov.on.ca/en/pro/programs/drugs/docs/compassionate_review_policy.pdf
aHUS Canada urges you to speak to your treating physician about this if you are hospitalized due to an immediate life-, limb-, or organ threatening complication.
For more information on how you can advocate for a long-term funding solution for Soliris for all Ontario aHUS patients, please contact aHUS Canada at firstname.lastname@example.org.